Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.
Showing 145–168 of 175
Bexorg has secured funding to validate TRPML1, a protein target for Parkinson's therapies, using preserved human brain tissue paired with AI-driven biomarker identification. This approach addresses a critical translational gap: the inability to confirm drug efficacy in human neural tissue, which has caused over 95% of CNS drug candidates to fail in clinical trials despite theoretical promise.
Intervertebral discs age slowly due to selective autophagy of HIF-1α under naturally hypoxic conditions. A small molecule designed to replicate this mechanism across tissues may extend mammalian lifespan by modulating how cells respond to low-oxygen environments.
Transposon Therapeutics received a $22 million ARPA-H grant to study TPN-101, a drug designed to inhibit LINE-1 retrotransposon activity and slow fundamental aging processes rather than treat individual diseases. The approach targets age-related inflammation driven by DNA elements that become dysregulated with age, potentially extending healthspan across multiple conditions simultaneously.
Aspen Neuroscience's autologous cell therapy for Parkinson's disease demonstrates early restoration of motor function and quality of life through transplantation of patient-derived dopamine-producing neurons into the brain. This represents a shift from symptomatic management toward biological reconstruction of damaged neural tissue.
Juvenescence's PAI-1 inhibitor MDI-2517 completed Phase 1 trials, demonstrating safety and tolerability for a once-daily oral therapy targeting inflammation and fibrosis—processes central to aging and age-related disease. Genetic evidence suggests PAI-1 reduction correlates with approximately 10 years of extended lifespan, positioning this mechanism as a meaningful target for aging intervention.
Cellular senescence plays a dual role in postpartum mammary gland remodeling—supporting normal tissue reorganization while simultaneously creating conditions that enhance tumor progression when oncogenic events coincide with gland involution. This mechanism reveals how a normally protective cellular state becomes pathogenic under specific developmental and genetic circumstances.
Mitorubin, a berberrubine-derived compound, restores mitochondrial function and protects cardiac tissue from age-related deterioration. This addresses a primary mechanism of cardiovascular aging by targeting energy production capacity at the cellular level.
Epia Neuro has launched an implantable brain-computer interface designed to help stroke survivors translate neural intent into functional movement through assistive devices. The approach prioritizes practical restoration of independence in daily life rather than speculative enhancement, addressing a significant gap in post-stroke rehabilitation where functional disability persists across years or decades.
Unlimited Bio initiated a Phase 1/2a trial combining AAV9-Follistatin and VEGF plasmid gene therapies to address age-related muscle decline, marking the first registered clinical study to combine these two approaches. The dual-therapy strategy targets both muscle growth signaling and vascular support, with safety and functional outcomes tracked over 12 months in adults aged 45 to 75.
Blue light exposure triggers excessive mitochondrial fragmentation in retinal cells through a specific protein (Drp1), driving cellular changes associated with age-related macular degeneration. Blocking this fragmentation restores mitochondrial function and reverses the pathological transformation in both cell cultures and animal models.
Evolve Science has launched a peptide and longevity platform that differentiates itself through supply chain transparency and batch-level documentation rather than marketing claims. The company sources products exclusively from FDA-registered US compounding pharmacies and requires Certificates of Analysis for every product, addressing a documented gap in quality verification within the longevity market.
Unnatural Products and Novartis have partnered to develop macrocyclic peptides—molecular structures between small molecules and biologics—targeting protein interactions implicated in cardiovascular disease and age-related conditions. This approach addresses a critical gap in drug development where conventional therapeutics cannot effectively engage disease-driving targets.
Research in senescent C. elegans reveals a hierarchical cascade of organ system failures rather than simultaneous deterioration, with specific tissues failing in sequence as aging progresses. This finding clarifies the mechanistic order of senescent decline and suggests that interventions targeting early failures in this cascade may prevent downstream system collapse.
Peptides represent a legitimate therapeutic class with demonstrated efficacy, but clinical validation is confined to a narrow subset of compounds. Most peptide applications currently marketed fall outside evidence-supported use, requiring practitioners to distinguish between established interventions and speculative applications.
The FDA granted Breakthrough Device Designation to CorTec's Brain Interchange, a fully implantable wireless brain-computer interface that uses closed-loop neural recording and adaptive stimulation to restore motor function in chronic stroke patients. Early clinical data show meaningful upper-limb recovery in patients whose progression had plateaued under conventional therapy.
Biophytis and LynxKite are expanding their AI-driven drug discovery partnership beyond sarcopenia to build a broader platform for age-related diseases, including dry age-related macular degeneration. The alliance demonstrates a concrete application of AI to accelerate candidate identification and reduce development timelines in longevity therapeutics.
Cognito Therapeutics and Ochsner Health are partnering to test Spectris, a non-invasive neuromodulation device that delivers synchronized light and sound stimulation to restore gamma oscillations disrupted in Alzheimer's disease. Early evidence shows the approach slows cognitive decline and reduces brain volume loss, with the collaboration designed to evaluate real-world clinical implementation across diverse healthcare settings.
BioAge Labs reported positive interim Phase 1 data for BGE-102, an oral NLRP3 inhibitor, demonstrating significant reductions in inflammatory cardiovascular biomarkers (hsCRP 86%, IL-6 58%, fibrinogen 30%) and brain penetration. The company is advancing toward Phase 2a trials in cardiovascular disease and expanding into ophthalmology for diabetic macular edema, positioning the compound as a multi-indication anti-inflammatory therapy.
A large epidemiological analysis of 15,050 participants found that higher intake of vitamins, particularly C and B2, correlates with slower biological aging as measured by multiple aging biomarkers. The association remained significant after adjustment for socioeconomic and lifestyle factors, suggesting a direct relationship between vitamin adequacy and the rate of biological aging.
Cognito Therapeutics and Ochsner Health have established a regional platform to evaluate Spectris, a non-invasive device that uses synchronized light and sound to stimulate gamma-frequency brain activity, alongside clinical infrastructure to assess its effectiveness in cognitive decline and Alzheimer's disease. The collaboratory will generate real-world data on treatment response, cost-effectiveness, and scalability across diverse populations.
Rubedo's RLS-1496, a GPX4 modulator designed to target senescent cells, met primary safety endpoints in a Phase 1 trial and demonstrated dose-dependent clinical improvements in psoriasis, atopic dermatitis, and photoaged skin within four weeks. The compound showed reduced senescent cell burden, decreased inflammatory markers, and increased collagen expression with no serious adverse events.
In aged ovarian cancer, elevated succinate in the tumor microenvironment drives metabolic reprogramming of regulatory T cells, amplifying immunosuppression and reducing survival. Pharmacological inhibition of succinate metabolism restores effector T cell activity and improves outcomes, identifying a metabolic mechanism underlying age-related cancer progression.
Noom acquired Tailor Made Compounding, a licensed 503A pharmacy operating across 46 states, to integrate prescription-grade therapies with behavioral coaching and establish a comprehensive preventive care platform. This move positions the company to expand beyond weight management into broader healthy aging interventions including peptide therapies and metabolic support.
A two-year study of 958 adults aged 70+ found that daily multivitamin use slowed biological aging markers measured through epigenetic clocks, with the effect most pronounced in participants showing accelerated aging. While the slowdown was modest—measured in months rather than years—the consistent effect across multiple aging biomarkers suggests multivitamins may influence cellular-level processes relevant to healthspan rather than lifespan extension.
